Helicos Hires Investment Bank to Advise on 'Strategic Alternatives,' Clarifies Instrument Placements | GenomeWeb

This article, originally published Sept. 3, has been updated with additional information.

By Julia Karow

Helicos BioSciences said last week that it has hired Thomas Weisel Partners "to assist the company with its evaluation and execution of strategic alternatives."

The company also clarified the number of instruments it has installed, as well as which of those instruments have been purchases as opposed to evaluation placements.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.